Gilead Sciences stock falls on potential HIV funding cuts
Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...
Polish News7h
New antibody studies boost hope for HIV cure
A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...
Unpacking the Latest Options Trading Trends in Gilead Sciences
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...
Yearly HIV prevention injection shows promise in clinical trial
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR
The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...
My Zimbabwe News15h
South African landmark HIV cure trial shows promising and outstanding results… despite President Trump cutting funding
In a moment of both triumph and uncertainty, South Africa's scientific community has unveiled encouraging results from a landmark HIV cure trial conducted in Durban, KwaZulu-Natal. The University of ...
Is Gilead Sciences, Inc. (GILD) a Best Biotech Stock According to Billionaires?
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...